ArticleHeart rhythm O22026
Cost-effectiveness of a novel antitachycardia pacing algorithm for the termination of ventricular tachyarrhythmias in the United States.
Article in Heart rhythm O2, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ventricular tachyarrhythmias are potentially life-threatening arrhythmias commonly managed with implantable cardioverter-defibrillators (ICDs). Conventional antitachycardia pacing (ATP) can reduce ICD shocks, but its effectiveness varies. Intrinsic antitachycardia pacing (iATP) is a novel algorithm designed to optimize ventricular tachycardia termination and minimize shocks. Objective: The purpose of this study was to evaluate the cost-effectiveness of iATP vs conventional ATP for terminating ventricular tachyarrhythmias in the United States. Methods: A Markov simulation model was developed to compare lifetime costs, survival, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) of iATP vs conventional ATP in patients with ICDs. Model inputs were derived from published literature, and analyses were performed from the perspective of an integrated US health care system. Sensitivity analyses assessed the robustness of findings. Results: Compared with conventional ATP, iATP was associated with additional QALYs (10.51 vs 10.33) and additional lifetime costs ($4014 vs $1673), resulting in a discounted ICER of $13,114 per QALY. The ICER is below the US willingness-to-pay (WTP) threshold ($120,000 per QALY). The finding of cost-effectiveness persisted across all sensitivity analyses. Conclusion: iATP was associated with clinical benefits and was determined to be a highly cost-effective strategy for managing ventricular tachyarrhythmias in patients with ICDs. The ICER remains below the willingness-to-pay threshold in both deterministic and probabilistic sensitivity analyses, demonstrating the robustness of the findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.